“Leaders In Care“
Wellness and community care entwine for PT Darya-Varia Laboratoria.
PT Darya-Varia Laboratoria Tbk or DVL, one of Indonesia’s leading pharmaceutical companies specializes in prescription drugs, consumer health and export/toll manufacturing. DVL, established in 1976, was the first manufacturing company in Indonesia to produce soft gelatin capsules. DVL products can be found in many countries in Asia, including the Philippines, Singapore, Malaysia, Vietnam, Myanmar and Mongolia. The conglomerate became a public-listed company in 1994 when it debuted on the Jakarta Stock Exchange.
The company’s flagship vitamin brands (Enervon C, Natur-E and Vicee) resiliently maintained market dominance through the Covid 19 pandemic. Indeed, Natur-E, Enervon, and Vicee improved their brand health tracking scores in their respective segments during 2020. However, amidst the shifting of health priorities within the pharmaceutical market owing to the Covid-19 pandemic, delivering immunity boosters and antiviral drugs became the focus of DVL’s endeavours in 2020.
At the end of 2020, DVL accelerated the import of Remdesivir (Remidia), a WHO-recommended antiviral drug for emergency use, thereby aiding the Indonesian government in the treatment of critical Covid-19 patients.
The advent of Covid-19 posed tremendous challenges in 2020 with disruptions to the global supply and demand chains, especially within the local toll business for prescription and cough medication. In spite of this, DVL persisted in distributing care kits consisting of PPEs, masks, vitamins, hand sanitizers to thousands of medical doctors, and provided donations via governmental institutions and professional organizations in mitigating the spread of the virus.
During the implementation of large-scale social lockdowns, DVL provided a transportation support facility for its skeleton team to ensure their health and safety. The management also adopted regular COVID-19 testing in addition to providing safety gear, multi-vitamins and groceries.
DVL has since diversified into more digitally-oriented endeavours with e-commerce and other prominent online platforms to widen the public’s access to DVL’s consumer health products. Reflecting the prevailing business conditions, DVL applies Corporate Social Responsibility (CSR) initiatives to its operational activities.
Both of DVL’s plants, in Gunung Putri and Citeureup, West Java, implement a water harvesting program by utilizing refill wells and adhering to strict standards and regulations. In addition, DVL utilizes domestic waste to produce fertilizer, and donates it to the local communities surrounding the plant.
DVL prides itself on adhering to GMP (Good Manufacturing Practices) standards established by the international regulatory authority, the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the Indonesian National Drug and Food Control Agency.
The company, in upholding the principles of equality, provides job opportunities regardless of gender, ethnicity, religion, race, social status or physical conditions. Notably, more than 52 percent of DVL’s permanent employees and ten out of its 22 top executives are female.
DVL has pledged to build a healthier Indonesia under the Sehat Indonesiaku campaign which aims to provide equal access to medical facilities for everyone. This commitment is realized through a number of health programs including the Healthy Village and Stunting Prevention projects.
The company also partnered with the SOS Children Village Foundation in disseminating health information and providing free medical check-ups for children. DVL also provides humanitarian assistance to areas affected by natural disasters, as well as annual donations to orphanages.
DVL’s achievements in the Indonesian Healthcare Industry have garnered numerous accolades, including multiple WOW Brand awards for its products. The company has also won several awards such as Infobrand’s Top Corporate Award for 2020 in recognition of its commitment to CSR programs.
“Market dominance for its brands gave PT Darya-Varia Laboratoria further impetus to do more for its consumers. Even during the covid 19 pandemic, the pharma giant continued to care for front liners while striving to keep up production on a skeleton staff.”
Shanggari Balakrishnan, Chief Executive Officer, MORS Group
Organised by
Knowledge Partner
News Distribution Partner
Trophy Partner
Supporting Partner
Copyright 2023 MORS GROUP (1084230-V) | ACES AWARDS | All Rights Reserved
